The therapeutic community is buzzing with anticipation surrounding retatrutide, a new dual GIP and GLP-1 agonist that’s exhibiting significant promise in clinical trials for addressing obesity. Unlike some existing weight loss approaches, retatrutide appears to provide a significant substantial reduction in body size and benefit metabolic health,